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18:485–91.ReplyAll Vasodilators Are Not Equal
We appreciate the commentary by Ms. Nel and Greaves regarding
our study (1). Previous studies have demonstrated that dipyr-
idamole, regadenoson, and adenosine all achieve maximal coronary
hyperemic ﬂow via endothelial-independent vasodilation of the
microvasculature (2–4). Although dobutamine stress has a different
mechanism of action, the resulting hyperemia is similar in magni-
tude to adenosine (5). More important, in both the larger cohort
from which this study was derived (6) and in other large cohorts (7),
the stressor used was not informative to the multivariable model
for predicting cardiac events. Accordingly, we do not believe that
the use of multiple stress agents is likely to have resulted in a type 1
error or a false-positive association between CFR and outcomes.
In response to concerns raised by Nel and Greaves regarding
incorporation bias, this problem occurs in diagnostic studies in which
the test being evaluated is available to referring clinicians, and thus,
may inﬂuence the diagnostic endpoint. In our study of prognosis,
CFR was not available to referring clinicians, and consequently,
could not have inﬂuenced clinical decision making. Furthermore, the
clinical endpoints were adjudicated blinded to CFR values. Finally,
for inclusion in this study, normal PET myocardial perfusion
imaging was deﬁned not on the basis of CFR, but rather on
semiquantitative interpretation of myocardial perfusion scans.
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Pulmonary Vein Isolation With
Versus Without Concomitant
Renal Artery Denervation in
Patients With Refractory
Symptomatic Atrial Fibrillation
and Resistant Hypertension
With the advent of renal artery denervation, numerous publications
have been forthcoming. Previously, we petitioned the Journal as well
as other publications about the lack of citation of our earlier studies
(1–6) using intravascular electrode catheters to ablate autonomic
nerves on the outside of blood vessels. We can appreciate the
reluctance of the Journal to include these citations at that time based
on the difference between the intravascular ablation of nerves in the
renal arteries affecting blood pressure (7,8) rather than intravascular
ablation of nerves outside of blood vessels affecting heart rate and
cardiac arrhythmias (9). However, recent reports have documented
the consistent and independent effects of renal sympathetic dener-
vation (RSD) on heart rate reduction (10,11). More conclusive
evidence supporting our contention is based on the experimental
studies of Zhao et al. (12) and the recent clinical study by Pokushalov
et al. (13), which have shown that RSD can be used to reduce the
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1130incidence of atrial ﬁbrillation. Although the exact mechanisms are
still unclear, it has been suggested that ablation of afferent nerves
arising from the renal arteries, or other arteries for that matter, can
reduce central sympathetic outﬂow back to the renal nerves as well as
via cardiac nerves to the heart, thereby affecting blood pressure (14)
as well as heart rate and cardiac arrhythmias (15). Therefore, we are
again requesting the Journal to consider including citations of our
previous work in future reports dealing with intravascular RSD for
resistant hypertension and other collateral beneﬁts.
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